Ф. А. Хабиров

2.5k total citations
39 papers, 452 citations indexed

About

Ф. А. Хабиров is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, Ф. А. Хабиров has authored 39 papers receiving a total of 452 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pathology and Forensic Medicine, 9 papers in Oncology and 7 papers in Neurology. Recurrent topics in Ф. А. Хабиров's work include Multiple Sclerosis Research Studies (19 papers), Polyomavirus and related diseases (6 papers) and Myofascial pain diagnosis and treatment (4 papers). Ф. А. Хабиров is often cited by papers focused on Multiple Sclerosis Research Studies (19 papers), Polyomavirus and related diseases (6 papers) and Myofascial pain diagnosis and treatment (4 papers). Ф. А. Хабиров collaborates with scholars based in Russia, United States and Belarus. Ф. А. Хабиров's co-authors include Т И Хайбуллин, Svetlana F. Khaiboullina, Albert A. Rizvanov, Г. В. Черепнев, Е. В. Мартынова, В. А. Парфенов, N. N. Yakhno, М. Л. Кукушкин, О.С. Давыдов and Е. Е. Ачкасов and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and Frontiers in Immunology.

In The Last Decade

Ф. А. Хабиров

31 papers receiving 433 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ф. А. Хабиров Russia 7 170 128 108 81 77 39 452
Hsu‐Tung Lee Taiwan 12 78 0.5× 85 0.7× 31 0.3× 48 0.6× 30 0.4× 30 466
Qiang Dong China 13 49 0.3× 39 0.3× 46 0.4× 59 0.7× 14 0.2× 20 387
Silvana Montella Italy 8 129 0.8× 39 0.3× 162 1.5× 23 0.3× 5 0.1× 13 409
Jonathan L. Carter United States 7 271 1.6× 46 0.4× 95 0.9× 42 0.5× 5 0.1× 12 468
A. Garcı́a-Merino Spain 11 156 0.9× 131 1.0× 105 1.0× 38 0.5× 4 0.1× 18 480
Pietro Familiari Italy 13 46 0.3× 34 0.3× 28 0.3× 50 0.6× 21 0.3× 38 522
Daying Zhang China 14 95 0.6× 92 0.7× 42 0.4× 24 0.3× 7 0.1× 31 417
Leila M. Boustany United States 8 39 0.2× 83 0.6× 96 0.9× 10 0.1× 32 0.4× 12 824
S Hashimoto Japan 11 23 0.1× 50 0.4× 32 0.3× 158 2.0× 15 0.2× 33 386
Masoud Nikanfar Iran 12 56 0.3× 18 0.1× 36 0.3× 77 1.0× 16 0.2× 38 389

Countries citing papers authored by Ф. А. Хабиров

Since Specialization
Citations

This map shows the geographic impact of Ф. А. Хабиров's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ф. А. Хабиров with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ф. А. Хабиров more than expected).

Fields of papers citing papers by Ф. А. Хабиров

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ф. А. Хабиров. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ф. А. Хабиров. The network helps show where Ф. А. Хабиров may publish in the future.

Co-authorship network of co-authors of Ф. А. Хабиров

This figure shows the co-authorship network connecting the top 25 collaborators of Ф. А. Хабиров. A scholar is included among the top collaborators of Ф. А. Хабиров based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ф. А. Хабиров. Ф. А. Хабиров is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Попова, Е. В., et al.. (2024). Early use of cladribine tablets for relapsing-remitting multiple sclerosis: Expert opinion. Meditsinskiy sovet = Medical Council. 101–107.
2.
Malkova, N A, С А Сиверцева, N. А. Totolyan, et al.. (2023). Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results. S S Korsakov Journal of Neurology and Psychiatry. 123(2). 52–52. 2 indexed citations
3.
Хабиров, Ф. А., et al.. (2023). Characteristics and dynamics of pathological changes in visual evoked potentials in multiple sclerosis. S S Korsakov Journal of Neurology and Psychiatry. 123(7). 88–88. 1 indexed citations
4.
Хабиров, Ф. А., et al.. (2022). An open prospective study of the efficacy and safety of therapy with a bioactive concentrate of small marine fish in patients with vertebrogenic lumboischialgia. SHILAP Revista de lepidopterología. 16(3). 60–66. 1 indexed citations
5.
Захарова, М. Н., et al.. (2022). New opportunities in the treatment of patients with multiple sclerosis (Resolution of the Council of Experts on April 23, 2022, Moscow, JSC «BIOCAD»). S S Korsakov Journal of Neurology and Psychiatry. 122(7). 84–84. 3 indexed citations
6.
Гусев, Е. И., et al.. (2022). Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial. S S Korsakov Journal of Neurology and Psychiatry. 122(1). 62–62. 6 indexed citations
7.
Brylev, Lev, М. Н. Захарова, D. S. Korobko, et al.. (2021). Consensus of expert advices on routing, diagnosis, and management of patients with neuromyelitis optica spectrum disorders. SHILAP Revista de lepidopterología. 13(5). 140–147. 1 indexed citations
8.
Evdoshenko, E. P., М. Н. Захарова, С. В. Котов, et al.. (2020). Updated recommendations of the Council of Experts on the use and safety of alemtuzumab (Lemtrada). S S Korsakov Journal of Neurology and Psychiatry. 120(3). 82–82. 2 indexed citations
9.
Хабиров, Ф. А., et al.. (2020). Comparison of the efficacy of Cellex and Cortexin in patients in the early recovery period of ischemic stroke. S S Korsakov Journal of Neurology and Psychiatry. 120(12). 11–11.
10.
Хабиров, Ф. А., et al.. (2018). The results of an open comparative retrospective trial of the course of multiple sclerosis during treatment with infibeta and other interferon-beta bioanalogues and glatiramer acetate. S S Korsakov Journal of Neurology and Psychiatry. 118(3). 18–18. 3 indexed citations
11.
Chataway, Jeremy, Keith F. Martin, Basil Sharrack, et al.. (2018). Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis. Neurology. 90(11). e955–e962. 73 indexed citations
12.
Хабиров, Ф. А., et al.. (2018). Progressive forms of multiple sclerosis. Practical medicine. 16(10). 39–42.
13.
Khaiboullina, Svetlana F., Marina Gomzikova, Ekaterina Martynova, et al.. (2017). Divergent Immunomodulation Capacity of Individual Myelin Peptides—Components of Liposomal Therapeutic against Multiple Sclerosis. Frontiers in Immunology. 8. 1335–1335. 10 indexed citations
14.
15.
Хабиров, Ф. А., et al.. (2017). Evaluation of efficiency and safety of adding neuromultivit to basic therapy of vertebrogenic radiculopathy. S S Korsakov Journal of Neurology and Psychiatry. 117(10). 38–38. 3 indexed citations
16.
Попова, Е. В., Anna N. Belova, N A Malkova, et al.. (2017). Primary progressive multiple sclerosis: current issues of timely diagnosis. S S Korsakov Journal of Neurology and Psychiatry. 117(10). 35–35. 2 indexed citations
17.
Захарова, М. Н., С. В. Котов, С. В. Прокопенко, et al.. (2017). A comparative placebo-controlled clinical study on the efficacy and safety of interferon beta-1a for subcutaneous injections in patients with remitting multiple sclerosis: results of the first year of observations. S S Korsakov Journal of Neurology and Psychiatry. 117(2. Vyp. 2). 107–107. 3 indexed citations
18.
Хабиров, Ф. А., et al.. (2012). Боли в шее и спине (диагностика, клиника и лечение). Practical medicine.
19.
Хабиров, Ф. А., et al.. (2011). [The complex approach to the rehabilitation of post-stroke patients with movement disorders in the early rehabilitation period].. PubMed. 111(4 Pt 2). 32–6. 1 indexed citations
20.
Хайбуллин, Т И, et al.. (2010). PATHOGENETIC HETEROGENITY OF MULTIPLE SCLEROSIS: KEY FOR UNDERSTANDING OF THE DISEASE CLINICAL POLYMORPHISM AND INDIVIDUALIZED THERAPY DEVELOPING. 54–65.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hsu‐Tung Lee Breakdown of academic impact, for papers by Qiang Dong Breakdown of academic impact, for papers by Silvana Montella Breakdown of academic impact, for papers by Jonathan L. Carter Breakdown of academic impact, for papers by A. Garcı́a-Merino Breakdown of academic impact, for papers by Pietro Familiari Breakdown of academic impact, for papers by Daying Zhang Breakdown of academic impact, for papers by Leila M. Boustany Breakdown of academic impact, for papers by S Hashimoto Breakdown of academic impact, for papers by Masoud Nikanfar
Rankless by CCL
2026